SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note Mar 7, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019 Feb 28, 2019
SCYNEXIS Announces Positive Interim Results from Phase 3 Open-Label FURI Study, Showing Oral Ibrexafungerp's Ability to Treat Refractory Fungal Infections and to Provide an Alternative to Long-Term IV Therapies Jan 30, 2019
SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors Jan 22, 2019
SCYNEXIS Announces FDA Agreement with Company-Proposed Phase 3 Vulvovaginal Candidiasis Program for Oral Ibrexafungerp Oct 23, 2018
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES) Oct 15, 2018
